Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3951-3960 Newer>

The Motley Fool August 1, 2007 Brian Lawler	ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth.
Pharmaceutical Executive July 3, 2007 Louis A. Morris	Culture Shock The withdrawal of Vioxx signaled a sea change. Welcome to the Culture of Drug Safety. The FDA is making changes in the way it reviews drug safety. Post-marketing staff has been enlarged 25%, and new, tougher laws are on the way.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Pharmaceutical Executive July 3, 2007 George Koroneos	In Sync with California Pharmaceutical companies everywhere are preparing themselves for compliance with California's Electronic-Pedigree Mandates, which go into effect 18 months from now. When in place, an inspector will be able to receive, immediately, a record of any drug's chain of custody.
Pharmaceutical Executive July 3, 2007 Walter Armstrong	Take Me to Your Leader Turnover in the top 10 pharmas has new CEOs racing to reinvent the way their companies do business. Running a large pharmaceutical company has becoming immensely complex, and requires a broad set of management skills. Even then, a CEO may never see a beloved molecule approved for drughood.
Pharmaceutical Executive July 3, 2007 Jill Wechsler	Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries.
Pharmaceutical Executive July 3, 2007 Patrick Clinton	From the Editor: Post-regulatory The Editor-in-Chief of this publication speaks out about drug safety, and drug availability, in the post-regulatory world.
Pharmaceutical Executive July 3, 2007 Sarah Houlton	Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap?
Pharmaceutical Executive July 3, 2007	Deals: Actavis Going Private? The board of the Icelandic generics maker holds out for a better offer.... Mylan Wins Merck Generics Unit... Genzyme to Acquire Bioenvision... etc.
Pharmaceutical Executive July 3, 2007 Humphrey Taylor	Opinion: Lead, Follow, or Get Out of the Way A comparative-effectiveness board is coming. The pharmaceutical industry's wise will embrace the change.
<Older 3951-3960 Newer> Return to current articles.